Wegovy® pill approved in the US as first oral GLP-1 for weight management - wegovy pill

Wegovy® pill approved in the US as first oral GLP-1 for weight management

Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events* Novo Nordisk expects to launch Wegovy® pill in the US in early January 2026 Dubai, 24 December 2025- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*. The Wegovy®

Editor  |   |  2 mins read
Read Full Story →
Noor Dubai Achieves 156% Growth in Treatment Services and Honours Its Supporting Partners - noor dubai

Noor Dubai Achieves 156% Growth in Treatment Services and Honours Its Supporting Partners

Dubai, United Arab Emirates, 12 December 2025: Noor Dubai Foundation, part of the Mohammed bin Rashid Al Maktoum Global Initiatives, announced that its national programme for the periodic screening and treatment of eye diseases in the United Arab Emirates has achieved a notable 156% increase in treatment cases, equivalent to 554 patients, between 2024 and 2025. The programme also recorded a 47% growth in free screenings and early detection services, with particular attention given to workers’ communities. The Foundation explained that these results were achieved through the expansion of partnerships with relevant entities and by strengthen

Editor  |   |  2 mins read
Read Full Story →